3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
43
Neoplasm Metastasis
5
Neoplasms
4
Ovarian Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Non-Small-Cell Lung
3
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Cancer Metastatic
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Lymphoma, Non-Hodgkin
1
Hyperglycemia
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Carcinosarcoma
1
Carcinoma, Lobular
1
Breast Neoplasms, Male
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma Of Esophagus
1
Interventions
volagidemab
2
dapagliflozin
1
Metformin
1
Insulin Glargine
1
Insulin Aspart
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hyperglycemia
×
Fulvestrant
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts